Patients with metastatic melanoma have a poor prognosis, with a 5‐year‐survival rate below 25%.1 Recently, the development of targeted therapies with BRAF and MEKis (BRAF and MEK inhibitors) has revolutionized the management and the prognosis of BRAFV600‐mutated melanoma patients. The gene discussed is BRAF; the disease is metastatic melanoma.